ECM
ENTA icon

Element Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Element Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,153
Closed -$397K – 400
2019
Q1 		$397K Buy
4,153
+202
+5% +$18.1K 0.01% 509
2018
Q4 		$280K Sell
3,951
-3,440
-47% -$264K 0.01% 471
2018
Q3 		$632K Buy
7,391
+3,070
+71% +$308K 0.01% 391
2018
Q2 		$501K Buy
4,321
+148
+4% +$14.8K 0.01% 371
2018
Q1 		$338K Buy
+4,173
New +$321K 0.01% 429

Other funds holding ENTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Element Capital Management's ENTA Position: Q2 2019 in Review

Element Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2019, closing a stake of 4,153 shares — an estimated $397K sold.

Element Capital Management first reported a position in ENTA in Q1 2018 and held it in 5 quarters. The position peaked at $632K in Q3 2018. 194 funds tracked by Wall St. Rank hold ENTA as of Q2 2019.

  • Element Capital Management reported no remaining Enanta Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Element Capital Management sold 4,153 Enanta Pharmaceuticals shares in Q2 2019, an estimated $397K.
  • Element Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Element Capital Management's Enanta Pharmaceuticals position peaked at $632K in Q3 2018.
  • 194 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2019.

Based on Element Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.